Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 21, 2026
Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosisKarlo Toljan, Brian Renner, Lynn Daboul, et al.
Neurology. Clinical Practice|July 10, 2020
Technology-enabled assessments to enhance multiple sclerosis clinical care and researchGabrielle Macaron, Brandon P Moss, Hong Li, et al.
Nature Reviews. Neurology|July 15, 2022
From the prodromal stage of multiple sclerosis to disease preventionRuth Ann Marrie, Mark Allegretta, Lisa F Barcellos, et al.
Imaging Neuroscience (Cambridge, Mass.)|October 15, 2025
Automated segmentation of multiple sclerosis lesions, paramagnetic rims, and central vein sign on MRI provides reliable diagnostic biomarkersFengling Hu, Zheng Ren, Luyun Chen, et al.
The Lancet. Neurology|September 20, 2025
2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosisFrederik Barkhof, Daniel S Reich, Jiwon Oh, et al.
Neurology|February 22, 2019
Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMSJiwon Oh, Daniel Ontaneda, Christina Azevedo, et al.
Neurology|September 2, 2025
Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis ClinicBrian Renner, Elizabeth Daphne Verter, Martina Absinta, et al.
Contemporary Clinical Trials|August 14, 2016
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosisRobert J Fox, Christopher S Coffey, Merit E Cudkowicz, et al.
Radiology|November 12, 2024
Aquaporin-4 Immunoglobulin G-seropositive Neuromyelitis Optica Spectrum Disorder MRI Characteristics: Data Analysis from the International Real-World PAMRINO Study CohortClaudia Chien, Vera Cruz E Silva, Emanuel Geiter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 31, 2026
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)Emma C Tallantyre, Sarah M Planchon, Harriet Howard, et al.
Pageof 19